Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Stefan SiebertLaura C CoatesLarissa Valor-MéndezSiba P RaychaudhuriWarner ChenSheng GaoLoqmane SeridiSoumya D ChakravartyMay ShawiFrederic LavieMohamed SharafMiriam ZimmermannAlexa P KollmeierXie L XuProton RahmanPhillip J MeaseAtul A DeodharPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
Guselkumab modulates IL-23 signaling and provides consistent pharmacodynamic effects in both biologic-naive and TNFi-IR PsA patients. Significantly elevated baseline IL-22, TNFα, and BD-2 levels and associations between baseline IL-22, IL-17A, and BD-2 levels and skin responses to guselkumab suggest greater dysregulation of IL-23/Th17 signaling in patients with TNFi-IR.